for people ages 18-65 (full criteria)
at Sacramento, California and other locations
study started
estimated completion



The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.

Official Title

A Study to Investigate the Safety, Tolerability , Pharmacokinetics of Single Ascending Dose of MT-3921 in Subjects With Acute Spinal Cord Injury


This is a Phase 1, open-label, single ascending dose study of MT-3921 in subjects with spinal cord injury.


Spinal Cord Injury Spinal Cord Injuries Wounds and Injuries MT-3921 Low dose MT-3921 High dose


You can join if…

Open to people ages 18-65

Additional screening criteria check may apply for qualification:

  • Provide written informed consent prior to beginning any study procedures
  • Cervical spinal cord injury, ASIA impairment scale grade A, B, and C with the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Neurological level of injury between C4 and C8
  • Male or female subjects aged between 18 and 65 years
  • Body mass index (BMI) <35
  • Has had stabilization surgery (if needed) following their SCI and prior to receiving MT-3921

You CAN'T join if...

Additional screening criteria check may apply for qualification:

  • Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
  • Poly-traumatic Injury as defined by Injury Severity Score (ISS) values > 25
  • Penetrating spinal cord injuries
  • Traumatic transection of the spinal cord or spinal cord contusion size > 3 cm determined by MRI
  • Any other significant pre-existing medical conditions prior to spinal cord injury or current conditions that, in the judgement of the iInvestigator, may increase the risks associated with study participation
  • Subjects with HIV, HBV or HCV positive
  • Psychoactive substance use disorder
  • History or presence of malignancy within the last 5 years prior to screening
  • Pregnant or nursing women
  • Subjects with hereditary fructose intolerance
  • History of anaphylaxis or significant allergy


  • UC Davis Medical Center not yet accepting patients
    Sacramento California 95816 United States
  • University of Southern California withdrawn
    Los Angeles California 90033 United States


accepting new patients
Start Date
Completion Date
Mitsubishi Tanabe Pharma Development America, Inc.
Sign up for this study
Phase 1
Study Type
Last Updated